Quick Take
Annovis Bio (OTC:ANVS) has filed to raise gross proceeds of up to $11.5 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on developing therapeutics for chronic and acute neurodegeneration disorders.
ANVS is a tiny firm seeking to solve problems that large, multinational pharma firms have been unable to make progress on.
I’ll provide an update when we learn more about the IPO.
Company & Technology
Berwyn, Pennsylvania-based-based Annovis Bio, previously known as QR Pharma, was founded in 2008 to develop therapeutics for the